CVE-2010-1021
Cross-site scripting (XSS) vulnerability in the Typo3 Quixplorer (t3quixplorer) extension before...
Cross-site scripting (XSS) vulnerability in the Typo3 Quixplorer (t3quixplorer) extension before 1.7.1 for TYPO3 allows remote attackers to inject arbitrary web script or HTML via unspecified vectors.
Exploit likelihood
What each source reports
NVD Score used
Cross-site scripting (XSS) vulnerability in the Typo3 Quixplorer (t3quixplorer) extension before 1.7.1 for TYPO3 allows remote attackers to inject arbitrary web script or HTML via unspecified vectors.
- Record
CVE-2010-1021- CVSS 2.0
- 4.3 Medium
AV:N/AC:M/Au:N/C:N/I:P/A:N - Weakness
- CWE-79
- Updated
- 2026-11-02
CVE List No score
Cross-site scripting (XSS) vulnerability in the Typo3 Quixplorer (t3quixplorer) extension before 1.7.1 for TYPO3 allows remote attackers to inject arbitrary web script or HTML via unspecified vectors.
- Record
CVE-2010-1021- Updated
- 2026-11-02
EUVDEUVD-2010-1054 No score
Cross-site scripting (XSS) vulnerability in the Typo3 Quixplorer (t3quixplorer) extension before 1.7.1 for TYPO3 allows remote attackers to inject arbitrary web script or HTML via unspecified vectors.
- Record
EUVD-2010-1054- Updated
- 2026-11-03
GitHub AdvisoriesGHSA-96h4-cv82-3xhm No score
Cross-site scripting (XSS) vulnerability in the Typo3 Quixplorer (t3quixplorer) extension before...
Cross-site scripting (XSS) vulnerability in the Typo3 Quixplorer (t3quixplorer) extension before 1.7.1 for TYPO3 allows remote attackers to inject arbitrary web script or HTML via unspecified vectors.
- Record
GHSA-96h4-cv82-3xhm- Weakness
- CWE-79
- Updated
- 2026-11-02
Affected products
History
| Recorded | Changed | Sources |
|---|---|---|
| aliases | EUVD | |
| first indexed | CVE List, GitHub Advisories, NVD |
Dates are when Every CVE recorded each change. Upstream dates may differ.
In short
CVE-2010-1021 is a medium vulnerability (CVSS 4.3) in Mads Brunn T3quixplorer, published March 19, 2010. No source lists public exploit code. EPSS puts the chance of exploitation in the next 30 days at 1.06%, the 64th percentile. No source names a fixed version.